Vehicle strategy follows the work.

Access Paths

Antigenic is built to support mission technology work through practical acquisition paths. Some programs require an existing vehicle. Others can move through direct agreements, partner-led structures, targeted procurements, or phased advisory-to-execution models.

We do not treat vehicle status as the strategy. The strategy is to match the program's urgency, risk, scope, and buyer constraints to an executable path that gets the right work under control.

Current Paths

Antigenic can support qualified opportunities through:

• Existing program structures where a buyer or industry lead has an active acquisition channel.
• Defined work packages with clear scope, acceptance criteria, delivery cadence, and governance expectations.
• Targeted direct opportunities where the work aligns to Antigenic's capacity, qualifications, and mission technology practices.
• Commercial or enterprise agreements for regulated organizations that need modernization, cyber, data, AI, or recovery execution outside a federal vehicle.

Pathway Assessment

During qualification, Antigenic works with acquisition and delivery stakeholders to clarify:

• Mission objective and operational consequence.
• Contract or agreement path.
• Scope boundaries and acceptance criteria.
• Staffing profile and mobilization timeline.
• Security, data, and compliance requirements.
• Reporting, governance, and escalation expectations.

Vehicle Roadmap

Antigenic will expand direct vehicle participation only where it supports the mission technology work we are built to perform. This page will be updated as formal vehicle access changes.

For immediate opportunities, submit details through Engagement Intake and identify any known acquisition constraints.